Q2 2025 Recap: 7 Pulmonology Updates to Know
Q2 2025 saw more research emerge in asthma therapeutics and management as well as rarer pulmonary diseases.
The second quarter of 2025 brought a wave of promising advances in pulmonology, with new data highlighting the potential of biologics, small molecules, and novel delivery platforms to address critical unmet needs in chronic respiratory diseases. Results presented at major conferences such as the American Thoracic Society (ATS) 2025 International Conference showcased targeted therapies poised to transform the treatment landscape for patients with COPD, pulmonary arterial hypertension (PAH), bronchiectasis, and idiopathic pulmonary fibrosis (IPF). Collectively, these findings reflect an accelerating push toward precision medicine approaches tailored to inflammatory and rare pulmonary conditions.